BioStock: Cereno completes CS014 trial ahead of June top-line data

Cereno Scientific announced today the successful completion of the second and final part of its phase I clinical trial evaluating drug candidate CS014 in healthy volunteers. The milestone was marked by the last patient’s last visit, and top-line results are expected in June 2025.

Read the article at biostock.se:

https://www.biostock.se/en/2025/04/cereno-completes-cs014-trial-ahead-of-june-top-line-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/